Guess Who Picked Up Rlj Lodging Trust (NYSE:RLJ) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Rlj Lodging Trust (NYSE:RLJ) reported that Goldman Sachs Asset Management, L.p. has picked up 13,397,956 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Goldman Sachs Asset Management, L.p. to a total of 13,397,956 representing a 10.8% stake in the company.
For those not familiar with the company, RLJ Lodging Trust is a real estate investment trust. The Company is engaged in the acquisition of focused-service and compact full-service hotels. The Company owns approximately 130 hotels with over 20,900 rooms, located in approximately 20 states and the District of Columbia, and an interest in a mortgage loan secured by a hotel. Its hotels’ brand affiliations include Residence Inn, Courtyard, SpringHill Suites, Marriott and Renaissance by Marriott; Hilton Garden Inn, Embassy Suites, DoubleTree, Hilton and Homewood Suites by Hilton, and Hyatt House, Hyatt Place and Hyatt by Hyatt. Its operating partnership is RLJ Lodging Trust, L.P. The Company’s properties include Courtyard San Francisco, Hyatt House Cypress Anaheim, Hyatt House Emeryville San Francisco Bay Area, Hyatt House San Ramon and Hyatt House Santa Clara in California, and Renaissance Boulder Flatiron Hotel, Residence Inn Boulder Louisville, Residence Inn Longmont Boulder and SpringHill Suites Boulder Longmont in Colorado.
A glance at Rlj Lodging Trust (NYSE:RLJ)’s key stats reveals a current market capitalization of 2.94 billion based on 124.30 million shares outstanding and a price at last close of $23.46 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-04, Ryan picked up 2,000 at a purchase price of $25.37. This brings their total holding to 2,000 as of the date of the filing.
On the sell side, the most recent transaction saw Hale unload 5,000 shares at a sale price of $25.00. This brings their total holding to 328,730.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Rlj Lodging Trust (NYSE:RLJ) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Goldman Sachs Group Inc. is Buying Retrophin Inc. (NASDAQ:RTRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Retrophin Inc. (NASDAQ:RTRX) reported that Goldman Sachs Group Inc. has picked up 696,852 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Goldman Sachs Group Inc. to a total of 696,852 representing a 1.8% stake in the company.
For those not familiar with the company, Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.
A glance at Retrophin Inc. (NASDAQ:RTRX)’s key stats reveals a current market capitalization of 821.45 million based on 37.73 million shares outstanding and a price at last close of $21.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-04, Meckler picked up 5,000 at a purchase price of $15.31. This brings their total holding to 52,000 as of the date of the filing.
On the sell side, the most recent transaction saw Aselage unload 3,200 shares at a sale price of $21.30. This brings their total holding to 240,556.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Retrophin Inc. (NASDAQ:RTRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Royal Bancshares Of Pennsylvania Inc. (NASDAQ:RBPAA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Royal Bancshares Of Pennsylvania Inc. (NASDAQ:RBPAA) reported that Bryn Mawr Bank Corp. has picked up 5,954,810 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Bryn Mawr Bank Corp. to a total of 5,954,810 representing a 21.1% stake in the company.
For those not familiar with the company, Royal Bancshares of Pennsylvania, Inc. is a bank holding company. The Company offers a range of financial and banking products and services. The principal activities of the Company are supervising Royal Bank America (Royal Bank), which engages in general banking business. It operates through two segments: Community Banking and Tax Liens. Its community banking segment consists of commercial and retail banking and equipment leasing. The community banking business segment includes Royal Bank and Royal Bank Leasing, and offers a range of products and services. Its tax liens segment includes ownership interest in Crusader Servicing Corporation and Royal Tax Lien Services, LLC. Royal Bank conducts business operations as a commercial bank offering consumer and business deposit products and services, and commercial and consumer loans, including home equity and small business administration loans. It also offers a range of services, such as cash management products and mobile deposits.
A glance at Royal Bancshares Of Pennsylvania Inc. (NASDAQ:RBPAA)’s key stats reveals a current market capitalization of 119.99 million based on 27.87 million shares outstanding and a price at last close of $4.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-05-05, Eller picked up 2,500 at a purchase price of $2.35. This brings their total holding to 19,900 as of the date of the filing.
On the sell side, the most recent transaction saw Eller unload 3,868 shares at a sale price of $1.81. This brings their total holding to 16,975.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Royal Bancshares Of Pennsylvania Inc. (NASDAQ:RBPAA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Infinity Property & Casualty Corp. (NASDAQ:IPCC) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Infinity Property & Casualty Corp (NASDAQ:IPCC) reported that Victory Capital Management Inc. has picked up 612,879 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Victory Capital Management Inc. to a total of 612,879 representing a 5.54% stake in the company.
For those not familiar with the company, Infinity Property and Casualty Corporation is a holding company that, through its subsidiaries, provides personal automobile insurance with a focus on the nonstandard market. The Company writes personal automobile insurance with a concentration on nonstandard automobile insurance, mono-line commercial vehicle insurance and classic collector automobile insurance. It also writes standard and preferred personal auto insurance, mono-line commercial auto insurance and classic collector automobile insurance. Personal Automobile is its insurance product, which provides coverage to individuals for liability to others for bodily injury and property damage and for physical damage to an insured’s own vehicle from collision and various other perils. Commercial Vehicle provides coverage to businesses for liability to others for bodily injury and property damage and for physical damage to vehicles from collision. Classic Collector provides protection for classic collectible automobiles.
A glance at Infinity Property & Casualty Corp. (NASDAQ:IPCC)’s key stats reveals a current market capitalization of 983.69 million based on 11.06 million shares outstanding and a price at last close of $87.60 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2012-12-21, Weinhoff picked up 1,000 at a purchase price of $57.75. This brings their total holding to 11,181 as of the date of the filing.
On the sell side, the most recent transaction saw Simon unload 4,500 shares at a sale price of $46.44. This brings their total holding to 74,392.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Infinity Property & Casualty Corp. (NASDAQ:IPCC) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Heron Therapeutics Inc. (NASDAQ:HRTX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Heron Therapeutics Inc. (NASDAQ:HRTX) reported that Broadfin Capital has picked up 3,916,534 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Broadfin Capital to a total of 3,916,534 representing a 9.99% stake in the company.
For those not familiar with the company, Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
A glance at Heron Therapeutics Inc. (NASDAQ:HRTX)’s key stats reveals a current market capitalization of 718.68 million based on 51.47 million shares outstanding and a price at last close of $13.55 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-19, Poyhonen picked up 10,000 at a purchase price of $12.20. This brings their total holding to 10,000 as of the date of the filing.
On the sell side, the most recent transaction saw Rosen unload 12,400 shares at a sale price of $23.89. This brings their total holding to 2,640.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Heron Therapeutics Inc. (NASDAQ:HRTX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Vanguard Group Inc. Picked Up Cognizant Technology Solutions Corp. (NASDAQ:CTSH) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Cognizant Technology Solutions Corp. (NASDAQ:CTSH) reported that Vanguard Group Inc. has picked up 39,165,838 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Vanguard Group Inc. to a total of 39,165,838 representing a 6.45% stake in the company.
For those not familiar with the company, Cognizant Technology Solutions Corporation is a provider of information technology (IT), consulting and business process services. The Company operates through four segments: Financial Services, which includes customers providing banking/transaction processing, capital markets and insurance services; Healthcare, which includes healthcare providers and payers, as well as life sciences customers, including pharmaceutical, biotech and medical device companies; Manufacturing, Retail and Logistics, which includes manufacturers, retailers, travel and other hospitality customers, as well as customers providing logistics services, and Other, which includes communications, manufacturing/retail/logistics, and high technology. The Company’s competencies include business, process, operations and IT consulting, application development and systems integration, enterprise information management, application testing, application maintenance and IT infrastructure services.
A glance at Cognizant Technology Solutions Corp. (NASDAQ:CTSH)’s key stats reveals a current market capitalization of 35.96 billion based on 606.60 million shares outstanding and a price at last close of $57.68 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-12-16, Patsalos-Fox picked up 10,000 at a purchase price of $51.70. This brings their total holding to 11,028 as of the date of the filing.
On the sell side, the most recent transaction saw Kandiah unload 20,000 shares at a sale price of $55.53. This brings their total holding to 12,072.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Cognizant Technology Solutions Corp. (NASDAQ:CTSH) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Coca Cola Co. (NYSE:KO) Shares is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Coca Cola Co. (NYSE:KO) reported that Vanguard Group Inc. has picked up 285,883,494 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Vanguard Group Inc. to a total of 285,883,494 representing a 6.62% stake in the company.
For those not familiar with the company, The Coca-Cola Company is a beverage company. The Company’s segments include Europe, Middle East and Africa; Latin America; North America; Asia Pacific; Bottling Investments, and Corporate. It markets, manufactures and sells beverage concentrates referred to as beverage bases, and syrups, including fountain syrups (concentrate business or concentrate operations), and finished sparkling and still beverages (finished product business or finished product operations). As of December 31, 2015, it owned or licensed and marketed over 500 non-alcoholic beverage brands, primarily sparkling beverages but also a range of still beverages, such as waters, enhanced waters, juices and juice drinks, ready-to-drink teas and coffees, and energy and sports drinks. As of December 31, 2015, it owned and marketed a range of nonalcoholic sparkling beverage brands, including Coca-Cola, Diet Coke, Fanta and Sprite. As of December 31, 2015, its finished beverage products are sold in more than 200 countries.
A glance at Coca Cola Co. (NYSE:KO)’s key stats reveals a current market capitalization of 172.62 billion based on 4.29 billion shares outstanding and a price at last close of $40.77 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-04-29, Gayle picked up 2,000 at a purchase price of $40.54. This brings their total holding to 3,000 as of the date of the filing.
On the sell side, the most recent transaction saw Goepelt unload 8,943 shares at a sale price of $41.75. This brings their total holding to 97,667.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Coca Cola Co. (NYSE:KO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Columbia Wanger Asset Management is Buying Celldex Therapeutics Inc. (NASDAQ:CLDX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Celldex Therapeutics Inc. (NASDAQ:CLDX) reported that Columbia Wanger Asset Management Llc. has picked up 6,195,855 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Columbia Wanger Asset Management Llc. to a total of 6,195,855 representing a 5.1% stake in the company.
For those not familiar with the company, Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
A glance at Celldex Therapeutics Inc. (NASDAQ:CLDX)’s key stats reveals a current market capitalization of 416.17 million based on 122.28 million shares outstanding and a price at last close of $3.45 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-08-25, Ellberger picked up 5,000 at a purchase price of $14.00. This brings their total holding to 53,500 as of the date of the filing.
On the sell side, the most recent transaction saw Catlin unload 25,000 shares at a sale price of $18.00. This brings their total holding to 35,109.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Celldex Therapeutics Inc. (NASDAQ:CLDX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.